Compare HALO & REG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HALO | REG |
|---|---|---|
| Founded | 1998 | 1963 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0B | 14.0B |
| IPO Year | 2001 | 1994 |
| Metric | HALO | REG |
|---|---|---|
| Price | $108.26 | $74.39 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 15 |
| Target Price | $78.64 | ★ $80.07 |
| AVG Volume (30 Days) | ★ 1.4M | 989.2K |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 3.80% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.11 | 0.46 |
| Revenue | $151,862,000.00 | ★ $1,553,524,000.00 |
| Revenue This Year | $28.24 | $3.04 |
| Revenue Next Year | $12.56 | $4.52 |
| P/E Ratio | ★ $34.47 | $162.22 |
| Revenue Growth | N/A | ★ 6.85 |
| 52 Week Low | $61.23 | $66.86 |
| 52 Week High | $111.15 | $83.66 |
| Indicator | HALO | REG |
|---|---|---|
| Relative Strength Index (RSI) | 64.98 | 40.06 |
| Support Level | $103.47 | $74.42 |
| Resistance Level | $111.15 | $76.97 |
| Average True Range (ATR) | 2.33 | 0.84 |
| MACD | -1.06 | 0.05 |
| Stochastic Oscillator | 59.05 | 26.64 |
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Regency Centers is one of the largest shopping center-focused retail REITs. The company's portfolio includes an interest in 481 properties, which includes over 58 million square feet of retail space following the completion of the Urstadt Biddle acquisition in August 2023. The portfolio is geographically diversified with 22 regional offices and no single market representing more than 12% of total company net operating income. Regency's retail portfolio is primarily composed of grocery-anchored centers, with 80% of properties featuring a grocery anchor and grocery stores representing 20% of annual base rent.